Comparative Pharmacology
Head-to-head clinical analysis: APONVIE versus EMETE CON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APONVIE versus EMETE CON.
APONVIE vs EMETE-CON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
APONVIE (pemigatinib) is a selective fibroblast growth factor receptor (FGFR) inhibitor. It binds to and inhibits FGFR1, FGFR2, and FGFR3, thereby suppressing FGFR signaling and reducing proliferation and survival of tumor cells with FGFR alterations.
Antiemetic; dopaminergic antagonist at D2 receptors in the chemoreceptor trigger zone; also exhibits anticholinergic and antihistaminic properties.
APONVIE is not a recognized drug; no dosing information available.
12.5 mg intravenously over 30 seconds as a single dose; may repeat once after 1 hour if necessary.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours in healthy adults; prolonged to 24–36 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 8-12 hours in adults with normal renal and hepatic function; may extend to 15-20 hours in elderly or patients with hepatic impairment.
APONVIE is primarily excreted renally as unchanged drug (approx. 70%) and via biliary/fecal routes (approx. 30%).
Primarily hepatic metabolism (CYP2D6, CYP3A4) with <5% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 60-70% of metabolites, with renal elimination of metabolites constituting 25-35%.
Category C
Category C
Antiemetic
Antiemetic